United States: Both Parties Seek En Banc Intervention In Amgen v. Sandoz

Last Updated: September 6 2015
Article by Aron Fischer

Last month, a divided panel of the Federal Circuit issued a split decision in Amgen v. Sandoz (summary; opinion). Amgen (in which Patterson Belknap represented one of the amici supporting Amgen) is the court's first decision interpreting the patent dispute resolution provisions of the Biologics Price Competition and Innovation Act (BPCIA). But if the parties have their way, the panel decision will not be the Federal Circuit's last word on the issues in dispute – and the court's next intervention may come sooner rather than later. Last week, both parties petitioned for en banc rehearing of the panel's decision. And on Wednesday, Amgen filed an emergency motion for an injunction pending en banc consideration and review, asking the full court to make a preliminary assessment of the issues before September 2, when the injunction issued by the original panel expires.

In Amgen, the panel (Judges Lourie, Newman, and Chen) addressed two provisions of the BPCIA "patent dance." The first was 42 U.S.C. § 262(l)(2)(A), which provides that biosimilar applicants "shall provide" reference product sponsors or innovators with "a copy of the application" and "such other information that describes the process or processes used to manufacture the biological product" after FDA accepts the application for review. Judge Lourie, joined by Judge Chen but with Judge Newman dissenting, ruled in favor of Sandoz on this issue, concluding that while paragraph (l)(2)(A) seems mandatory when "read in isolation," an applicant does "not violate" the BPCIA by withholding the required information; instead, the innovator's "only remedies" are to bring claims for patent infringement and declaratory relief under 35 U.S.C. § 271(e) and 42 U.S.C. § 262(l)(9)(C).

The second provision addressed by Amgen is 42 U.S.C. § 262(l)(8)(A), which states that an applicant "shall provide notice to the reference product sponsor not later than 180 days before the date of the first commercial marketing of the biological product licensed under" the BPCIA. On this issue, all three judges agreed with Amgen that the notice could not be given until the proposed biosimilar product had been "licensed," or approved, by FDA. The majority, with Judge Chen dissenting on this issue, went on to hold that Sandoz could not market its biosimilar product Zarxio until 180 days after it provided a post-approval notice of commercial marketing. The majority therefore kept a previously issued interim injunction against Sandoz in place until September 2, when the 180-day notice period expires.

The parties' petitions for en banc review largely track the arguments they made in their briefing on appeal. Amgen contends that the language of paragraph (l)(2)(A) is mandatory, full stop, and that the statutory rights to bring a claim for patent infringement or declaratory relief are not, strictly speaking, remedies at all – let alone exclusive remedies – for failure to provide the specified pre-litigation information. Sandoz, in its petition, argues that the panel misread the statute as requiring post-approval notice of commercial marketing because the word "licensed" in paragraph (l)(8)(A) "simply refers to the product that will be marketed" not to the product at the time of notice – and that the majority "compounded its error" by holding that the notice was mandatory and enforceable. On Tuesday, August 25, the Federal Circuit called for the parties to respond to each other's petitions. Those responses are due September 8.

Meanwhile, on Wednesday August 26, Amgen filed an emergency motion, for injunctive relief pending en banc consideration, asking the full court to "preserve the status quo" after the injunction issued by the Amgen panel expires on September 2. Yesterday, on August 27, Sandoz filed a letter response asking for permission to respond on August 31 and contending that "any 'emergency' is entirely of Amgen's own making" since it could have moved for injunctive relief at any time since the July 21 panel decision. The Federal Circuit usually decides emergency motions for interim relief quickly. Although the court does not usually issue substantive opinions on these motions, its disposition of them is often informative (though by no means decisive) as to the ultimate outcome of the appeal. That was certainly the case for Amgen's previous motion for interim relief pending the panel decision; the panel granted the motion without comment and later issued its opinion keeping the interim injunction in effect.

The Amgen panel's decision to keep the interim injunction in place until September 2 also raises an interesting issue related to Sandoz's en banc petition. Although the panel clearly ruled for Amgen as to paragraph (l)(8)(A) and granted Amgen full relief (i.e., a 180-day injunction), its formal disposition of the issue was to dismiss Amgen's appeal as moot in light of its decision to extend the interim injunction for the full 180-day period. This disposition raises the question whether Sandoz's en banc petition on paragraph (l)(8)(A) is also moot (or will become moot when the injunction expires on September 2). Sandoz argues that the issue is not moot because it requested a bond pending appeal on which it can recover, and because the paragraph (l)(8)(A) controversy falls under the "capable of repetition, yet evading review" exception to mootness. The issue certainly is capable of repetition, as it has already been raised in two pending BPCIA actions (Janssen v. Celltrion, where Patterson Belknap is co-counsel for the plaintiff, and Amgen v. Apotex). Whether or not the full court decides to take up the paragraph (l)(8)(A) issue (or Amgen's paragraph (l)(2)(A) issue) in this appeal, it is unlikely that either question will evade en banc review in the long run.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.